Unicycive-logo-new-white

Unicycive Therapeutics, Inc.

Unicycive Therapeutics is a biopharma company with development programs focused on two kidney diseases with largely unmet medical needs. 

Nasdaq: UNCY
IR Website: https://ir.unicycive.com/
Headquarters: Los Altos, CA

It is developing Renazorb* (lanthanum dioxycarbonate) an investigational phosphate binding agent using proprietary nanoparticle technology for the treatment of patients with hyperphosphatemia. They are also developing UNI-494, a novel new chemical entity that targets mitochondrial dysfunction which is in late preclinical development for the treatment of acute kidney injury.


TALK TO MANAGEMENT

The Unicycive Therapeutics management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form and we will connect you shortly.

*RENAZORB™ (lanthanum dioxycarbonate) is an unapproved investigational new drug being developed under FDA’s 505(b)(2) regulatory procedure. 

Unicycive Therapeutics At-A-Glance

Addressing Important Unmet Needs

Renazorb: Utilizing Proven Mechanisms of Action

UNI-494: Focused on Mitochondria

Investor Presentation

Press Releases

Stock Chart (Intraday)

Stock Chart (Historical)

Stock Detail

SEC Filings

Video: Unicycive’s Doug Jermasek, EVP-Corporate Development Talks Medication Compliance

A Large Addressable Market

Deftly Navigating the Regulatory Maze

Digging into the Science

Management Overview

Risks & Disclosures

Unicycive-logo-new-white

The Unicycive Therapeutics management and investor relations team is available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

• Directly hear the Unicycive Therapeutics story
• Ask your questions
• Submit the form below and someone will get in touch with you as soon as possible

Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.